Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

Preparation and use of P2T receptor antagonists in AstraZeneca's portfolio

Sep. 13, 1999

Another market introduction for Merck's short-acting antiplatelet agent Aggrastat

Sep. 9, 1999

ME-3230, an orally active prodrug of a potent gpIIb/IIIa antagonist

Aug. 31, 1999

Oral bioavailability of thrombin inhibitor S-31922 shows reduced variability in the presence of food

Aug. 30, 1999

Servier researchers present S-31214, a potent and selective thrombin inhibitor, at ACS

Aug. 30, 1999

Emisphere Technologies foresees initiation of phase III testing for oral heparin

Aug. 30, 1999

SR-123781A, a novel heparin mimetic with advantages over standard heparin

Aug. 27, 1999

Double prodrug UR-3216, a potent, long-lasting and orally active gpIIb/IIIa antagonist

Aug. 27, 1999

Corvas enters rNAPc2 manufacturing agreement in anticipation of phase III trials

Aug. 27, 1999

Roche Canada obtains licensing and marketing rights to TNK-tPA

Aug. 26, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.